Mechanisms underlying cancer growth and apoptosis by DEK overexpression in colorectal cancer

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Lin, Lijuan ^a,b   Piao, Junjie ^a   Ma, Yibing ^c   Jin, Tiefeng ^a   Quan, Chengshi ^d   Kong, Jienan ^a   Li, Yulin ^d   Lin, Zhenhua ^a  

^a YANBIAN UNIVERSITY MEDICAL COLLEGE   (China)

^b EASTERN LIAONING UNIVERSITY   (China)

^c Department of Pathology Dandong Centre Hospital   (China)

^d Basic Medical College   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; DEK PROTEIN; KI 67 ANTIGEN; ONCOPROTEIN; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P53; UNCLASSIFIED DRUG; BCL2 PROTEIN, HUMAN; DEK PROTEIN, HUMAN; NONHISTONE PROTEIN; SMALL INTERFERING RNA; TP53 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER TISSUE; CARCINOGENESIS; CELL PROLIFERATION; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DRUG TARGETING; FLOW CYTOMETRY; GENETIC TRANSFECTION; GROWTH INHIBITION; HCT116 CELL LINE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FAMILY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SW 620 CELL LINE; UPREGULATION; COLORECTAL TUMOR; DISEASE COURSE; ENZYMOLOGY; FLUORESCENCE MICROSCOPY; GENE EXPRESSION PROFILING; INTESTINE MUCOSA; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMOSOMAL PROTEINS, NON-HISTONE; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; HCT116 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; INTESTINAL MUCOSA; KI-67 ANTIGEN; MICROSCOPY, FLUORESCENCE; ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84908577858     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0111260     Document Type: Article

References (45)

1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29.
2. Jeong KE, Cairns JA (2013) Review of economic evidence in the prevention and early detection of colorectal cancer. Health Econ Rev 3: 20.
3. Wang J, Wang X, Lin S, Chen C, Wang C, et al. (2013) Identification of kininogen-1 as a serum biomarker for the early detection of advanced colorectal adenoma and colorectal cancer. PLoS One 8: e70519.
4. Ohno K, Fujimori T, Okamoto Y, Ichikawa K, Yamaguchi T, et al. (2013) Diagnosis of desmoplastic reaction by immunohistochemical analysis, in biopsy specimens of early colorectal carcinomas, is efficacious in estimating the depth of invasion. Int J Mol Sci 14: 13129-13136.
5. Lin L, Piao J, Gao W, Piao Y, Jin G, et al. (2013) DEK over expression as an independent biomarker for poor prognosis in colorectal cancer. BMC Cancer 13: 366.
6. von Lindern M, van Baal S, Wiegant J, Raap A, Hagemeijer A, et al. (1992) Can, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 39 half to different genes: characterization of the set gene. Mol Cell Biol 12: 3346-3355.
7. Khodadoust MS, Verhaegen M, Kappes F, Riveiro-Falkenbach E, Cigudosa JC, et al. (2009) Melanoma proliferation and chemoresistance controlled by the DEK oncogene. Cancer Res 69: 6405-6413.
8. Riveiro-Falkenbach E, Soengas MS (2010) Control of tumorigenesis and chemoresistance by the DEK oncogene. Clin Cancer Res 16: 2932-2938.
9. Shibata T, Kokubu A, Miyamoto M, Hosoda F, Gotoh M, et al. (2010) DEK oncoprotein regulates transcriptional modifiers and sustains tumor initiation activity in high-grade neuroendocrine carcinoma of the lung. Oncogene 29: 4671-4681.
10. Secchiero P, Voltan R, di Iasio MG, Melloni E, Tiribelli M, et al. (2010) The oncogene DEK promotes leukemic cell survival and is downregulated by both Nutlin-3 and chlorambucil in B-chronic lymphocytic leukemic cells. Clin Cancer Res 16: 1824-1833.
11. Sammons M, Wan SS, Vogel NL, Mientjes EJ, Grosveld G, et al. (2006) Negative regulation of the RelA/p65 transactivation function by the product of the DEK proto-oncogene. J Biol Chem 281: 26802-26812.
12. Kourennyi DE, Liu X, Barnes S (2002) Modulation of rod photoreceptor potassium Kx current by divalent cations. Ann Biomed Eng 30: 1196-1203.
13. Gamble MJ, Fisher RP (2007) SET and PARP1 remove DEK from chromatin to permit access by the transcription machinery. Nat Struct Mol Biol 14: 548-555.
14. Wise-Draper TM, Morreale RJ, Morris TA, Mintz-Cole RA, Hoskins EE, et al. (2009) DEK proto-oncogene expression interferes with the normal epithelial differentiation program. Am J Pathol 174: 71-81.
15. Kappes F, Fahrer J, Khodadoust MS, Tabbert A, Strasser C, et al. (2008) DEK is a poly(ADP-ribose) acceptor in apoptosis and mediates resistance to genotoxic stress. Mol Cell Biol 28: 3245-3257.
16. Wise-Draper TM, Mintz-Cole RA, Morris TA, Simpson DS, Wikenheiser-Brokamp KA, et al. (2009) Overexpression of the cellular DEK protein promotes epithelial transformation in vitro and in vivo. Cancer Res 69: 1792-1799.
17. Wise-Draper TM, Allen HV, Thobe MN, Jones EE, Habash KB, et al. (2005) The human DEK proto-oncogene is a senescence inhibitor and an upregulated target of high-risk human papillomavirus E7. J Virol 79: 14309-14317.
18. Carro MS, Spiga FM, Quarto M, Di Ninni V, Volorio S, et al. (2006) DEK Expression is controlled by E2F and deregulated in diverse tumor types. Cell Cycle 5: 1202-1207.
19. Shi MD, Lin HH, Lee YC, Chao JK, Lin RA, et al. (2008) Inhibition of cell-cycle progression in human colorectal carcinoma Lovo cells by andrographolide. Chem Biol Interact 174: 201-210.
20. Saito S, Yamamoto H, Mukaisho K, Sato S, Higo T, et al. (2013) Mechanisms underlying cancer progression caused by ezrin overexpression in tongue squamous cell carcinoma. PLoS One 8: e54881.
21. Jin A, Xu Y, Liu S, Jin T, Li Z, et al. (2013) Sineoculis homeobox homolog 1 protein overexpression as an independent biomarker for pancreatic ductal adenocarcinoma. Exp Mol Pathol 96: 54-60.
22. Merkel CA, da Silva Soares RB, de Carvalho AC, Zanatta DB, Bajgelman MC, et al. (2010) Activation of endogenous p53 by combined p19Arf gene transfer and nutlin-3 drug treatment modalities in the murine cell lines B16 and C6. BMC Cancer 10: 316.
23. Huang L, Xu Y, Cai G, Guan Z, Cai S (2012) Downregulation of S100A4 expression by RNA interference suppresses cell growth and invasion in human colorectal cancer cells. Oncol Rep 27: 917-922.
24. Datta A, Adelson ME, Mogilevkin Y, Mordechai E, Sidi AA, et al. (2011) Oncoprotein DEK as a tissue and urinary biomarker for bladder cancer. BMC Cancer 11: 234.
25. Kurokawa H, Zhang M, Matsumoto S, Yamashita Y, Tanaka T, et al. (2005) The relationship of the histologic grade at the deep invasive front and the expression of Ki-67 antigen and p53 protein in oral squamous cell carcinoma. J Oral Pathol Med 34: 602-607.
26. Khan R, Khan AQ, Lateef A, Rehman MU, Tahir M, et al. (2013) Glycyrrhizic acid suppresses the development of precancerous lesions via regulating the hyperproliferation, inflammation, angiogenesis and apoptosis in the colon of Wistar rats. PLoS One 8: e56020.
27. Borralho PM, Simões AE, Gomes SE, Lima RT, Carvalho T, et al. (2011) miR-143 overexpression impairs growth of human colon carcinoma xenografts in mice with induction of apoptosis and inhibition of proliferation. PLoS One 6: e23787.
28. Wu Q, Li Z, Lin H, Han L, Liu S, et al. (2008) DEK overexpression in uterine cervical cancers. Pathol Int 58: 378-382.
29. Wise-Draper TM, Allen HV, Jones EE, Habash KB, Matsuo H, et al. (2006) Apoptosis inhibition by the human DEK oncoprotein involves interference with p53 functions. Mol Cell Biol 26: 7506-7519.
30. Béroud C, Soussi T (2003) The UMD-p53 database: new mutations and analysis tools. Hum Mutat 21: 176-181.
31. Liu Y, Chen Y, Lu X, Wang Y, Duan Y, et al. (2012) SCYL1BP1 modulates neurite outgrowth and regeneration by regulating the Mdm2/p53 pathway. Mol Biol Cell 23: 4506-4514.
32. Kubbutat MH, Vousden KH (1998) Keeping an old friend under control: regulation of p53 stability. Mol Med Today 4: 250-256.
33. Marine JC, Francoz S, Maetens M, Wahl G, Toledo F, et al. (2006) Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4. Cell Death Differ 13: 927-934.
34. Zheng B, Wu L, Ma L, Liu S, Li L, et al. (2013) Telekin induces apoptosis associated with the mitochondria-mediated pathway in human hepatocellular carcinoma cells. Biol Pharm Bull 36: 1118-1125.
35. Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR (2010) The BCL-2 family reunion. Mol Cell 37: 299-310.
36. Wang C, Youle RJ (2009) The role of mitochondria in apoptosis. Annu Rev Genet 43: 95-118.
37. Autret A, Martin SJ (2009) Emerging role for members of the Bcl-2 family in mitochondrial morphogenesis. Mol Cell 36: 355-363.
38. Kang MH, Reynolds CP (2009) Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 15: 1126-1132.
39. Green DR (2005) Apoptotic pathways: ten minutes to dead. Cell 121: 671-674.
40. Scovassi AI, Poirier GG (1999) Poly (ADP-ribosylation) and apoptosis. Mol Cell Biochem 199: 125-137.
41. Xiao CX, Yang XN, Huang QW, Zhang YQ, Lin BY, et al. (2013) ECHS1 acts as a novel HBsAg-binding protein enhancing apoptosis through the mitochon-drial pathway in HepG2 cells. Cancer Lett 330: 67-73.
42. Privette Vinnedge LM, Kappes F, Nassar N, Wells SI (2013) Stacking the DEK: from chromatin topology to cancer stem cells. Cell Cycle 12(1): 51-66.
43. Privette Vinnedge LM, Benight NM, Wagh PK, Pease NA, Nashu MA, et al. (2014) The DEK oncogene promotes cellular proliferation through paracrine Wnt signaling in Ron receptor-positive breast cancers. Oncogene. doi: 10.1038/onc.2014.173. [Epub ahead of print]
44. Karam M, Thenoz M, Capraro V, Robin JP, Pinatel C, et al. (2014) Chromatin redistribution of the DEK oncoprotein represses hTERT transcription in leukemias. Neoplasia 16(1): 21-30.
45. Kim DW, Chae JI, Kim JY, Pak JH, Koo DB, et al. (2009) Proteomic analysis of apoptosis related proteins regulated by proto-oncogene protein DEK. J Cell Biochem 106(6): 1048-1059.